PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease | MicrobiomeTrials← Back to trialsNCT05928039
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2023-10-25Est. Completion: 2027-07-30
Enrollment target: 210 participants Locations- University of Calgary, Calgary, Alberta, Canada
- University of Alberta IBD Clinic, Edmonton, Alberta, Canada
- GI Research Institute (G.I.R.I), Vancouver, British Columbia, Canada
- West Coast Gastroenterology, Vancouver, British Columbia, Canada
- Nova Scotia Health Victoria, Halifax, Nova Scotia, Canada
- GNRR Digestive Clinics and Research Center Inc., Brampton, Ontario, Canada
- GNRR Digestive Clinics and Research Center Inc, Brampton, Ontario, Canada
- Rajbir Rai Medical Corporation, Brantford, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- London Digestive Disease Institute, London, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- West GTA Research Inc., Mississauga, Ontario, Canada
- West GTA Research Inc, Mississauga, Ontario, Canada
- ABP Research Services Corp., Oakville, Ontario, Canada
- Taunton Surgical Center, Oshawa, Ontario, Canada
- The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026
Sinai Health System, Toronto, Ontario, CanadaTIDHI Clinic, Toronto, Ontario, CanadaCentre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, CanadaHôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, CanadaResearch Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, CanadaUniversité de Sherbrooke, Sherbrooke, Quebec, CanadaPhase 4
Recruiting
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 pa…
Miami, United StatesEst. completion Sep 1, 2027